ArticleBlood cancer discovery2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Blood cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06879340 (A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies), which is not on this map. Cited by 124 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
10.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
Who cites it
124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.Frontiers in immunology · 2025Pooled it
- The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: a systematic review of current literature.Frontiers in medicine · 2025Pooled it
- Decade-long persistence of CD19 CAR T cells in B cell lymphomas.Nature medicine · 2026Trial
- CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.Cancer research communications · 2026Trial
- Trial
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.Blood advances · 2022Trial
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysis.Human vaccines & immunotherapeutics · 2026Article
- Review
- Minimal residual disease by high-throughput sequencing in standard risk-favorable pediatric B-lymphoblastic leukemia.Blood advances · 2026Article
- Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood cancer discovery · 2026Review
- Article
- Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatric drugs · 2026Review
- Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.Haematologica · 2026Article
- B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.Cancers · 2026Review
- Non-specific Clones Hamper the Reliability of Immunoglobulin Light Chain Gene Rearrangements in Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Cohort Study.Annals of laboratory medicine · 2026Observational
- CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.Molecular therapy. Oncology · 2026Review
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 15 institutions in 7 countries.
Michael A Pulsipher *Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. michael.pulsipher@hci.utah.edu.
Xia Han *Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Shannon L MaudeDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Theodore W LaetschDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-8497-3138
Muna QayedDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0001-7689-343X
Susana RivesPediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0002-5658-1831
Michael W BoyerDepartment of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah.
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan.ORCID 0000-0003-3136-5670
Gregory A YanikMichigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children's Hospital, Ann Arbor, Michigan.
Tim DriscollPediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina.
G Doug MyersPediatric Hematology and Oncology, Children's Mercy Hospital; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Peter BaderDivision for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany.
Andre BaruchelPediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France.ORCID 0000-0003-0120-6089
Jochen BuechnerDepartment of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5848-4501
Heather E StefanskiDepartment of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota.
Creton KalfoglouNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Kevin NguyenNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Edward R WaldronNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Karen Thudium MuellerNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Harald J MaierNovartis Pharmaceuticals Corporation, Basel, Switzerland.
Gabor KariNovartis Pharmaceuticals Corporation, Basel, Switzerland.
Stephan A GruppDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Novartis (United States) · USChildren's Hospital of Philadelphia · USNovartis (Switzerland) · CHChildren's Hospital of Los Angeles · USChildren's Mercy Hospital · USC. S. Mott Children's Hospital · USDuke University · USEmory University · USGoethe University Frankfurt · DEHospital Sant Joan de Déu Barcelona · ESKyoto University · JPOslo University Hospital · NOParisTech · FRUniversity of Minnesota Medical Center · USUniversity of Utah · US
Funding
Vascular Training GrantT32HL007950 · NHLBI · YALE UNIVERSITY · PI JEFFREY R. BENDER, Daniel Greif · 2000 to 2026
$9.6MNHLBI NIH HHS T32 HL007950
Abstract
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (
Indexed as
Precursor Cell Lymphoblastic Leukemia-LymphomaAntigens, CD19ChildHigh-Throughput Nucleotide SequencingHumansNeoplasm, ResidualReceptors, Antigen, T-CellRecurrenceYoung AdultAntigens, CD19Receptors, Antigen, T-Celltisagenlecleucel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06879340ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.